Bausch & Lomb Incorporated
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bausch & Lomb Incorporated sits in the top decile of US sponsors by registered trial count (#170 of 15,742 sponsors by registered trial count).
Bausch & Lomb Incorporated: 174 sponsored US clinical trials, 3 recruiting.
Bausch & Lomb Incorporated sponsors 174 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 158 completed. 60 of these trials are in Phase 3-4 (later-stage) and 42 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myopia, with 9 trials.
Top-decile sponsor footprint
Bausch & Lomb Incorporated ranks in the top decile of sponsors by registered trial count (#170 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
158 of 166 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
174 total, page 2 of 4
Clinical Study of Approved Contact Lenses
NCT03351101
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
NCT03145025
Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations
NCT03098953
LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT02786901
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
NCT01060787
A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution
NCT02701556
Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL
NCT02394379
Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris
NCT02394340
Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact Lens
NCT02258139
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT02208297
Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants
NCT01959243
Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.
NCT02039765
Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT01996839
Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness
NCT01959230
Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
NCT01895972
Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers
NCT01895985
A Study to Evaluate a Mid Add Multi-Focal Soft Contact Lens
NCT01959178
Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.
NCT01475643
Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
NCT01817582
A Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact Lens
NCT01873846
Hydrophobic Acrylic Toric IOL Designed to Reduce the Effects of Preoperative Corneal Astigmatism
NCT01852084
Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days
NCT01736462
Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
NCT01740388
Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT01749904
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT01749930
Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
NCT01753739
Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation
NCT01736527
BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT01707381
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT01591161
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT01591655
Evaluation of Ocular Comfort With ISTA Tears vs Systane
NCT01650584
A Study to Evaluate the Product Feasibility of Two New Silicone Hydrogel Contact Lenses
NCT01583868
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
NCT01722604
A Study to Evaluate the Feasibility of a High Add Multi Focal Contact Lens
NCT01518868
A Study to Evaluate the Product Performance of a Low Add MultiFocal Soft Contact Lens
NCT01539694
Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis
NCT01578278
A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens
NCT01412983
A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens
NCT01416142
Safety and Efficacy of a Contact Lens for Daily Disposable Use
NCT01365039
Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
NCT01367249
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
NCT01330355
A Study to Evaluate a Modified Contact Lens
NCT01391364
Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact Lenses
NCT01416272
Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis
NCT01289431
Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers
NCT01317030
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery
NCT01298752
Evaluation of Two Daily Disposable Contact Lenses.
NCT01300065
Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension
NCT01223378
A Study to Evaluate a New Silicone Hydrogel Contact Lens
NCT01309893
Evaluation of a New Silicone Hydrogel Contact Lens
NCT01309880
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 26 |
| Phase 3 | 46 |
| Phase 4 | 14 |
Therapeutic Areas
What is open in the Bausch & Lomb Incorporated pipeline
3 recruiting of 174 indexed (2% open); 158 completed (91%).
Phase mix: 60 late (III/IV) vs 42 early (I/II) (balanced across stages).
Top condition: Myopia (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bausch & Lomb Incorporated: open-pipeline peers nationwide
Peers matched on 174 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Bausch & Lomb Incorporated sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 174 trials (± recruiting share)
- Albert Einstein College of Medicine · 175 trials · 11% recruiting
- UConn Health · 178 trials · 11% recruiting
- Tufts Medical Center · 169 trials · 11% recruiting
- Baylor Research Institute · 180 trials · 17% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Medtronic Cardiac Rhythm and Heart Failure · 2% recruiting · 115 trials
- Eisai · 2% recruiting · 287 trials
- Lexicon Pharmaceuticals · 2% recruiting · 56 trials
- Alcon Research · 2% recruiting · 275 trials
Related
What to do with this Bausch & Lomb Incorporated page
174 registered trials is a research-attention snapshot, not an endorsement of Bausch & Lomb Incorporated or any single study.
- 3 of Bausch & Lomb Incorporated's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Myopia is the condition Bausch & Lomb Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myopia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bausch & Lomb Incorporated pipeline card: 174 registered trials from official public datasets.Report a data error.